{"id":9668,"date":"2016-08-14T06:44:12","date_gmt":"2016-08-14T06:44:12","guid":{"rendered":"http:\/\/revoscience.com\/en\/?p=9668"},"modified":"2016-08-14T06:44:12","modified_gmt":"2016-08-14T06:44:12","slug":"vedanta-strikes-deal-to-develop-microbiome-infused-immunotherapies","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/vedanta-strikes-deal-to-develop-microbiome-infused-immunotherapies\/","title":{"rendered":"Vedanta Strikes Deal to Develop Microbiome-Infused Immunotherapies"},"content":{"rendered":"<div class=\"panel-pane pane-entity-field pane-node-field-body-paragraphs\">\n<div class=\"pane-content\">\n<div class=\"paragraphs-items paragraphs-items-field-body-paragraphs paragraphs-items-field-body-paragraphs-full paragraphs-items-full\">\n<div class=\"field field-name-field-body-paragraphs field-type-paragraphs field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item odd\">\n<div class=\"entity entity-paragraphs-item paragraphs-item-embedded-text\" style=\"font-weight: normal;\">\n<div class=\"content\">\n<div class=\"field field-name-field-embedded-text field-type-text-long field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\"><a href=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-9669\" src=\"http:\/\/revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg\" alt=\"ddd1608_bacteria\" width=\"800\" height=\"600\" title=\"\" srcset=\"https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg 800w, https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria-300x225.jpg 300w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/a>Vedanta Biosciences, a Cambridge, Massachusetts-based startup specializing in drugs derived from the microbiome, and the NYU Langone Medical Center will collaborate on creating a new class of cancer treatments.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">It will be a two-pronged investigation, which will focus on the role bacteria residing in people\u2019s guts could play in impacting the efficacy of checkpoint inhibitors and then conduct clinical trials to assess the potency of potential microbiome immunotherapies,\u00a0<a style=\"color: inherit;\" href=\"http:\/\/www.businesswire.com\/news\/home\/20160810006199\/en\/Vedanta-Biosciences-Announces-Collaboration-NYU-Langone-Medical\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">according to Vedanta\u2019s announcement.<\/span><\/a><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cCheckpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy, and some patients who respond will eventually relapse,\u201d said Dr. Bruce Roberts, chief scientific officer of Vedanta in a statement.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">\u201cRecent data suggest an important role for the microbiome in the anti-tumor activity of immunotherapy, and our other studies of the microbiome will offer interesting new clinical insights into how and why these treatments work. Further understanding of the role of the microbiome in immunotherapeutic responses against cancer may also lead to new and improved therapies,\u201d elaborated Roberts.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">This news comes a little over a month after Vedanta gained an additional $50 million in funding to help in part with advancing its other microbiome drug candidates into clinical testing,\u00a0<a style=\"color: inherit;\" href=\"http:\/\/www.xconomy.com\/boston\/2016\/06\/06\/vedanta-nabs-50m-to-expand-microbiome-into-immune-boosting-therapies\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000;\">wrote\u00a0<em>Xconomy.<\/em><\/span><\/a><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">One candidate for inflammatory bowel disease, labeled is VE-202, should start its first clinical trial later this year with development assistance provided by Johnson &amp; Johnson.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">There were no financial details disclosed regarding the NYU deal.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vedanta Biosciences, a Cambridge, Massachusetts-based startup specializing in drugs derived from the microbiome, and the NYU Langone Medical Center will collaborate on creating a new class of cancer treatments.<\/p>\n","protected":false},"author":6,"featured_media":9669,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,26,17],"tags":[],"class_list":["post-9668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biology","category-medicine","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",800,600,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria-150x150.jpg",150,150,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria-300x225.jpg",300,225,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",750,563,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",750,563,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",800,600,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",800,600,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",800,600,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",760,570,false],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",600,450,false],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",600,450,false],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",653,490,false],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",480,360,false],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",87,65,false],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",640,480,false],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",96,72,false],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2016\/08\/ddd1608_bacteria.jpg",150,113,false]},"author_info":{"info":["Amrita Tuladhar"]},"category_info":"<a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/biology\/\" rel=\"category tag\">Biology<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/health\/medicine\/\" rel=\"category tag\">Medicine<\/a> <a href=\"https:\/\/www.revoscience.com\/en\/category\/news\/research\/\" rel=\"category tag\">Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/9668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=9668"}],"version-history":[{"count":0,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/9668\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/9669"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=9668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=9668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=9668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}